These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 125803)

  • 1. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.
    Walsh PC; Siiteri PK
    J Urol; 1975 Aug; 114(2):254-6. PubMed ID: 125803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
    Bélanger A; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.
    Ahmann FR; Crawford ED; Kreis W; Levasseur Y
    Cancer Res; 1987 Sep; 47(17):4736-9. PubMed ID: 3621171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
    Ayub M; Levell MJ
    Clin Endocrinol (Oxf); 1990 Mar; 32(3):329-39. PubMed ID: 2140542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma androgen levels after subcapsular orchiectomy or estrogen treatment for prostatic carcinoma.
    Vermeulen A; Schelfhout W; De Sy W
    Prostate; 1982; 3(2):115-21. PubMed ID: 6211662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.
    Carmina E; Lobo RA
    Obstet Gynecol; 1991 Nov; 78(5 Pt 1):845-9. PubMed ID: 1833685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men.
    Baba S; Murai M; Jitsukawa S; Hata M; Tazaki H
    J Urol; 1978 Mar; 119(3):375-80. PubMed ID: 642094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer.
    Bélanger A; Brochu M; Cliche J
    J Clin Endocrinol Metab; 1986 May; 62(5):812-5. PubMed ID: 2937801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possibility of adrenal-testicular interaction as indicated by plasma androgens in response to HCG in men with normal, suppressed and impaired adrenal function.
    Nieschlag E; Kley HK
    Horm Metab Res; 1975 Jul; 7(4):326-30. PubMed ID: 125219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketoconazole therapy in advanced prostatic cancer.
    Trachtenberg J
    J Urol; 1984 Jul; 132(1):61-3. PubMed ID: 6328052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.
    Schiller CD; Schneider MR; Hartmann H; Graf AH; Klocker H; Bartsch G
    Urol Res; 1991; 19(1):7-13. PubMed ID: 1827559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocrine effects of spironolactone used as an antiandrogen.
    Young RL; Goldzieher JW; Elkind-Hirsch K
    Fertil Steril; 1987 Aug; 48(2):223-8. PubMed ID: 2956130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
    Lukkarinen O; Hammond GL; Kontturi M; Vihko R
    Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are adrenal and testicular androgen levels correlated?
    Georgiadis EI; Matzoros C; Aliferis C; Batrinos M
    Horm Metab Res; 1992 Oct; 24(10):488-91. PubMed ID: 1464416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy.
    Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A; Stege R; von Schoultz B
    Prostate; 1989; 14(2):177-82. PubMed ID: 2523531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.
    Studen KB; Sebestjen M; Pfeifer M; Prezelj J
    Eur J Endocrinol; 2011 Mar; 164(3):389-95. PubMed ID: 21156647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adrenal androgens on the transplantable human prostate tumor PC-82.
    van Weerden WM; van Kreuningen A; Elissen NM; de Jong FH; van Steenbrugge GJ; Schröder FH
    Endocrinology; 1992 Dec; 131(6):2909-13. PubMed ID: 1446627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.